Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma-Reference-Cited by-同舟云学术

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

Published:2019-07-24 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Klemen Nicholas D.,Wang Melinda,Feingold Paul L.,Cooper Kirsten,Pavri Sabrina N.,Han Dale,Detterbeck Frank C.,Boffa Daniel J.,Khan Sajid A.,Olino Kelly,Clune James,Ariyan Stephan,Salem Ronald R.,Weiss Sarah A.,Kluger Harriet M.,Sznol Mario,Cha Charles^ORCID

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0672-3.pdf

Reference29 articles.

1. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119–27.

2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. JCO. Proc Am Soc Clin Oncol. 1999;17:2105–16.

3. Rosenberg SA, Packard BS, Aebersold PM. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676–80.

4. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, et al. Randomized, prospective evaluation comparing intensity of Lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol American Society of Clinical Oncology. 2016;34(20):2389–97.

5. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–7.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer;Expert Review of Anticancer Therapy;2024-06-14

2. Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study;Frontiers in Oncology;2024-03-05

3. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression;Liver Cancer;2024-02-01

4. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series;International Journal of Gynecologic Cancer;2024-01-31

5. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma;European Journal of Cancer;2024-01